Heart:氯吡格雷可以降低房颤PCI术后患者出血风险

2020-03-30 MedSci原创 MedSci原创

本研究旨在比较第三代P2Y12抑制剂与氯吡格雷联合口服抗凝(OAC)和阿司匹林治疗经皮冠状动脉介入治疗(PCI)心房颤动(AF)的安全性和有效性。

本研究旨在比较第三代P2Y12抑制剂与氯吡格雷联合口服抗凝(OAC)和阿司匹林治疗经皮冠状动脉介入治疗(PCI)心房颤动(AF)的安全性和有效性。

本次荟萃分析包括前瞻性和回顾性研究,比较了房颤患者行PCI术后出血和主要不良心脏事件(MACE)的双重和三重抗血栓治疗方案。最终共纳入分析了来自7个临床研究的22014名患者,在接受OAC联合P2Y12抑制剂治疗的患者中,90%有接受氯吡格雷治疗,8%接受替卡格雷治疗,2%接受普拉格雷治疗。与氯吡格雷相比,替卡格雷和普拉格雷会增加患者出血的风险,但在MACE的发生率方面无明显差异。

研究结果显示,在房颤PCI术后接受OAC治疗的患者中,氯吡格雷可以降低出血的风险。

原始出处:

Florentino L et al.P2Y12 inhibitors with oral anticoagulation for percutaneous coronary intervention with atrial fibrillation: a systematic review and meta-analysis.Heart.2020 Mar.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1633850, encodeId=c6a5163385026, content=<a href='/topic/show?id=578d13843ad' target=_blank style='color:#2F92EE;'>#PCI术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13843, encryptionId=578d13843ad, topicName=PCI术)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ea4322051797, createdName=zxl736, createdTime=Tue Nov 24 16:25:05 CST 2020, time=2020-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1357463, encodeId=9011135e463ce, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Wed Apr 01 01:25:05 CST 2020, time=2020-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1486442, encodeId=03ac1486442a9, content=<a href='/topic/show?id=76291384571' target=_blank style='color:#2F92EE;'>#PCI术后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13845, encryptionId=76291384571, topicName=PCI术后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4ea78134582, createdName=12499e01m49暂无昵称, createdTime=Wed Apr 01 01:25:05 CST 2020, time=2020-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1563277, encodeId=919315632e730, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Wed Apr 01 01:25:05 CST 2020, time=2020-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1031246, encodeId=cb2e103124614, content=房颤,临床上碰到很多哦, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=心介, createdTime=Mon Mar 30 13:25:05 CST 2020, time=2020-03-30, status=1, ipAttribution=)]
    2020-11-24 zxl736
  2. [GetPortalCommentsPageByObjectIdResponse(id=1633850, encodeId=c6a5163385026, content=<a href='/topic/show?id=578d13843ad' target=_blank style='color:#2F92EE;'>#PCI术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13843, encryptionId=578d13843ad, topicName=PCI术)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ea4322051797, createdName=zxl736, createdTime=Tue Nov 24 16:25:05 CST 2020, time=2020-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1357463, encodeId=9011135e463ce, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Wed Apr 01 01:25:05 CST 2020, time=2020-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1486442, encodeId=03ac1486442a9, content=<a href='/topic/show?id=76291384571' target=_blank style='color:#2F92EE;'>#PCI术后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13845, encryptionId=76291384571, topicName=PCI术后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4ea78134582, createdName=12499e01m49暂无昵称, createdTime=Wed Apr 01 01:25:05 CST 2020, time=2020-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1563277, encodeId=919315632e730, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Wed Apr 01 01:25:05 CST 2020, time=2020-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1031246, encodeId=cb2e103124614, content=房颤,临床上碰到很多哦, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=心介, createdTime=Mon Mar 30 13:25:05 CST 2020, time=2020-03-30, status=1, ipAttribution=)]
    2020-04-01 zhaojie88
  3. [GetPortalCommentsPageByObjectIdResponse(id=1633850, encodeId=c6a5163385026, content=<a href='/topic/show?id=578d13843ad' target=_blank style='color:#2F92EE;'>#PCI术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13843, encryptionId=578d13843ad, topicName=PCI术)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ea4322051797, createdName=zxl736, createdTime=Tue Nov 24 16:25:05 CST 2020, time=2020-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1357463, encodeId=9011135e463ce, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Wed Apr 01 01:25:05 CST 2020, time=2020-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1486442, encodeId=03ac1486442a9, content=<a href='/topic/show?id=76291384571' target=_blank style='color:#2F92EE;'>#PCI术后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13845, encryptionId=76291384571, topicName=PCI术后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4ea78134582, createdName=12499e01m49暂无昵称, createdTime=Wed Apr 01 01:25:05 CST 2020, time=2020-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1563277, encodeId=919315632e730, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Wed Apr 01 01:25:05 CST 2020, time=2020-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1031246, encodeId=cb2e103124614, content=房颤,临床上碰到很多哦, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=心介, createdTime=Mon Mar 30 13:25:05 CST 2020, time=2020-03-30, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1633850, encodeId=c6a5163385026, content=<a href='/topic/show?id=578d13843ad' target=_blank style='color:#2F92EE;'>#PCI术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13843, encryptionId=578d13843ad, topicName=PCI术)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ea4322051797, createdName=zxl736, createdTime=Tue Nov 24 16:25:05 CST 2020, time=2020-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1357463, encodeId=9011135e463ce, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Wed Apr 01 01:25:05 CST 2020, time=2020-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1486442, encodeId=03ac1486442a9, content=<a href='/topic/show?id=76291384571' target=_blank style='color:#2F92EE;'>#PCI术后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13845, encryptionId=76291384571, topicName=PCI术后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4ea78134582, createdName=12499e01m49暂无昵称, createdTime=Wed Apr 01 01:25:05 CST 2020, time=2020-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1563277, encodeId=919315632e730, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Wed Apr 01 01:25:05 CST 2020, time=2020-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1031246, encodeId=cb2e103124614, content=房颤,临床上碰到很多哦, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=心介, createdTime=Mon Mar 30 13:25:05 CST 2020, time=2020-03-30, status=1, ipAttribution=)]
    2020-04-01 slcumt
  5. [GetPortalCommentsPageByObjectIdResponse(id=1633850, encodeId=c6a5163385026, content=<a href='/topic/show?id=578d13843ad' target=_blank style='color:#2F92EE;'>#PCI术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13843, encryptionId=578d13843ad, topicName=PCI术)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ea4322051797, createdName=zxl736, createdTime=Tue Nov 24 16:25:05 CST 2020, time=2020-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1357463, encodeId=9011135e463ce, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Wed Apr 01 01:25:05 CST 2020, time=2020-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1486442, encodeId=03ac1486442a9, content=<a href='/topic/show?id=76291384571' target=_blank style='color:#2F92EE;'>#PCI术后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13845, encryptionId=76291384571, topicName=PCI术后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4ea78134582, createdName=12499e01m49暂无昵称, createdTime=Wed Apr 01 01:25:05 CST 2020, time=2020-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1563277, encodeId=919315632e730, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Wed Apr 01 01:25:05 CST 2020, time=2020-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1031246, encodeId=cb2e103124614, content=房颤,临床上碰到很多哦, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=心介, createdTime=Mon Mar 30 13:25:05 CST 2020, time=2020-03-30, status=1, ipAttribution=)]
    2020-03-30 心介

    房颤,临床上碰到很多哦

    0

相关资讯

JACC:心梗过程中静脉注射他汀类药物可能明显减少心肌损伤

除降脂外,他汀类药物还具有心脏保护作用。大剂量他汀类药物治疗似乎可以减少高危患者的心血管并发症。但是他汀类治疗理想的时机和管理体制仍然未知。本研究比较了心肌梗死(MI)时静脉注射他汀类药物与心肌梗死后

JACC:近一半的心脏病孕妇并发症是可预防的

妊娠可能导致心脏病妇女的并发症,这些并发症可能危及生命。了解严重的并发症以及如何预防是很重要的。本研究的主要目的是评估心脏病孕妇的严重心脏病事件(SCEs)的发生率,以及其是否可预防和对新生儿预后的影

盘点:JACC三月第五期研究一览

1. 富含脂质与不富含脂质冠脉支架植入的预后比较研究

Heart:中国东北的房颤流行病学研究

本研究的目的旨在评估中国东北的房颤流行病学特征。

JACC:低剂量alteplase会增加ST段抬高型心梗患者微血管阻塞风险

微血管阻塞影响一半ST段抬高心肌梗死患者的预后。本研究旨在确定冠状动脉再灌注后早期低剂量冠状动脉内注射alteplase治疗策略的有效性和安全性是否与缺血时间有关。

JACC:神经体液阻断剂的停用对心衰患者的影响

在心脏再同步化治疗后显示正常射血分数的心力衰竭患者中使用神经体液阻滞剂的必要性尚不清楚。本研究的目的是探讨心脏再同步化治疗后正常射血分数患者停用神经体液阻断剂的可行性和安全性。